PharmaShots | Incisive News in 3 Shots

Subscribe Now

Mismatch Repair Deficient

Merck's Keytruda (pembrolizumab) Receives EC's Approval as 1L Treatment for Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer

Merck's Keytruda (pembrolizumab) Receives EC's Approval as 1L Treatment for Metastatic Microsatellite Instability-High (MSI-H) or...

January 27, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us